Association of 5-alpha-reductase inhibitor and prostate cancer incidence and mortality: a meta-analysis

Abstract

In conclusion, while male 5-ARI users were associated with a decreased risk of overall prostate cancer and increased risk of high-grade prostate cancer (Gleason 8-10), they were not associated with an increased risk of overall or prostate cancer mortality. 5-ARIs should be recommended carefully for use as chemopreventive agents.